Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...

Losing excess weight would in turn improve health. For example, lower levels of sleep apnoea – when breathing stops and ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a study ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

As 2025 approaches, the healthcare landscape is undergoing rapid transformation. Rising healthcare utilization, escalating ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

When we think about the immune system, we usually associate it with fighting infections. However, a study published in Science by the Champalimaud Foundation reveals a surprising new role.